The classic trap
Recital 34 broadens the definition of genetic data well beyond clinical DNA testing. Any analysis of a biological sample yielding equivalent information (RNA sequencing, chromosomal analysis, even recreational saliva tests) falls under article 9 GDPR. The CNPD and CNIL regularly sanction laboratories, fertility clinics, nutrigenomics start-ups and HR services that collect such data without a specific article 9(2) legal basis, without prior DPIA, and without reinforced security measures. The trap: assuming that because you don't perform medical diagnosis, you are not concerned.
The real scope of genetic data under recital 34
- Chromosomal analyses (karyotype, FISH, CGH-array) performed in medical biology laboratories.
- Whole or targeted DNA sequencing, including pharmacogenomic tests used to adapt treatment.
- RNA analyses (transcriptomics, COVID PCR tests retained beyond immediate diagnosis).
- Consumer genealogy tests (MyHeritage, 23andMe) marketed in Luxembourg via partners.
- Paternity tests, non-invasive prenatal tests (NIPT), newborn screenings.
- Research biobanks, samples stored at CHL, LIH or IBBL for later reanalysis.
- Any derived data yielding equivalent information: epigenetic profile, methylation, microbiome in certain contexts.
Why this recital changes your DPIA
As soon as a processing operation involves genetic data as defined in recital 34, a DPIA becomes mandatory (article 35(3)(b) and the CNPD list of processing requiring DPIA). The legal basis can only be explicit consent (article 9(2)(a)), vital interest, public health or scientific research with appropriate safeguards. Technical measures must exceed standard practice: salted hash pseudonymisation, encryption at rest with HSM, strict segregation between raw genetic data and identification data, exhaustive access logging.
How Luxgap automates this risk
Our Luxgap Genetic Data Guardian closes the ultra-sensitive data topic by turning every genetic flow into a traceable vault, opposable to the CNPD. The tool connects directly to your laboratory LIMS (Glims, Modulab, Molis), your sequencing platforms (Illumina BaseSpace, Oxford Nanopore EPI2ME), your biobank storage (IBBL pipeline) and your HR or clinical systems, to map in real time every data falling under the broadened scope of recital 34.
- Automatically detects the presence of genetic data in your connected systems by scanning FHIR, HL7 schemas and FASTQ/VCF/BAM files, even when stored in a misclassified directory.
- Classifies each flow according to the EDPB grid (Guidelines 03/2020 on health research) and identifies the applicable article 9 legal basis, with alerts when none holds.
- Generates the article 35 DPIA pre-filled specifically for genetic data, integrating CNPD recommendations and prior consultation when residual risk justifies it.
- Continuously verifies the compliance of technical measures (encryption, pseudonymisation, RBAC access control) against ISO 27799 and ENISA guidelines for health data.
- Alerts via Teams or email as soon as a new sequencing pipeline exports data to a non-EU cloud without Schrems II-validated standard contractual clauses.
- Produces a cryptographically sealed timestamped PDF report, opposable during a CNPD audit, demonstrating article 5(2) accountability on this high-risk processing.
Available as a complement to a Luxgap DPO mandate or as a dedicated SaaS module depending on your scope. Request a tailored quote and our teams will prepare a demonstration on your real pipelines, with a free 48h white audit to measure your exposure before any commitment.
